NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE

What North American Society for the Study of Celiac Disease does

The organization over time

Each line starts at 100 in 2019, so what you read is the shape rather than the size: 150 means half as much again as 2019, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.

Balance sheet

Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $231k to $110k (−52%).

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 4 of the last 7 reported years ran a deficit.

Who funds it, year by year

2018 → 2023: the base held at 1 funder, grant income fell $442 → $40.

1 of 6 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 0% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.

From the IRS filings of NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE leans on a few funders — its largest provides 98% of grant income and the top three 100%; half comes from just 1 funder.

98% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE.

Largest funder’s share by year: 2018 100% · 2019 99% · 2020 64% · 2021 100% · 2023 100% — broadly stable.

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

Where its funders are

NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE draws 100% of its grant income from funders outside California, across 4 states in all.

Funder states come from each funder’s own filing. $100 arriving through sponsors registered in 1 state is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.